Evaluation of Spirometry Results in Men with COPD Consuming Opioid at First Visit to the Lung Clinic

Document Type : Research Paper

Authors

1 Associate Professor, Department of Internal Medicine, Faculty of Medicine, Islamic Azad University, Yazd Branch, Yazd, Iran

2 Internal Resident, Department of Internal Medicine, Faculty of Medicine, Fasa University of Medical Sciences, Fasa, Iran

3 Graduated from General Medicine, Faculty of Medicine, Islamic Azad University, Yazd Branch, Yazd, Iran

10.22038/mjms.2026.88851.5045

Abstract

Introduction: In this study, the spirometry findings of men suffering from chronic obstructive pulmonary disease in opioid users were compared to the control group in the first visit of patients with respiratory complaints to the clinic.
Methods: The present study is a cross-sectional study and the sample was randomly selected from men who referred tohe lung clinic of Afshar Yazd Hospital with respiratory complaints in 2019. The sample was divided into two groups of 60 people with opioid addiction and a group of 90 non-addicted people, and spirometry was taken from the patients, and the MMRCdyspnea scale was used to determine the severity of dyspnea. Then the data was entered into SPSS software and analyzed.
Results: In this study, there were150 patients with an average age of 59.78 ± 10.95 years.124 patients were smokers and 26 patients had quit smoking.There was no significant difference in consumption status and amount of consumption based on Pack/year, averageBMI and distribution of grade of dyspnea severity based on MMRC in two groups. In two groups, grades1 and 2 have the most frequency of shortness of breath. There was a significant difference in mean FEV1 and FVC, FEV1/FVC and FEF25-75 between the two groups, in age under 60,current smoking status, BMI under 25, Pack/year rate over 30, and grades 1 and 2 of dyspnea severity. It is more obvious.
Conclusion: It can be concluded thatpeople with opioid addiction have lower values in spirometry results than non-addicted people, due to the delay in the first visit.

Keywords

References

  1.  

    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD [Internet] [updated 2016]. Available from: http://www.goldcopd.org.
    2. Johannessen A, Lehmann S, Omenaas ER, Eide GE, Bakke PS, Gulsvik A. Post- bronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med. 2006; 173 (2):1316-1325.
    3. Ogura T, Egan T. Chapter 15-Opioid Agonists and Antagonists. Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application. Philadelphia, PA: Elsevier/Saunders.2013.
    4. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet. 2004; 364 (9434):613-620.
    5. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinico Economics and Outcomes Research. 2013; 5: 235-245.
    6. Mannino DM, Kiriz VA. Changing the burden of COPD mortality. International Journal of Chronic Obstructive Pulmonary Disease. 2006; 1(3):219-233.
    7. Rycroft CE, Heyes A, Lanza L, Becker K. Epidemiology of chronic obstructive pulmonary disease: a literature review. International Journal of Chronic Obstructive Pulmonary Disease. 2012; 7:457-494.
    8. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007; 370 (9589): 765-773.
    9. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186 (2):155-61.
    10. Fishaman PA. Fishman's Manual of Pulmonary Diseases and Disorders. Indian Journal of Chest Disease and Allied Science. 2004; 46:63.
    11. Javad Mousavi SA, Yadollah Zadeh M, Hossein Nejad Yazdi M, Adeli SH. Spirometric Assessment of Patients Having Opium Smoking Addiction and Pulmonary Complications. Razi Journal of Medical Sciences. 2005; 12 (46):267-74.
    12. Mehta S, Parmar N, Kelleher M, Jolley CJ, White P, Durbaba S, et al. COPD and asthma in patients with opioid dependency: a cross-sectional study in primary care. NPJ Primary Care Respiratory Medicine. 2020; 30 (1):1-6.
    13. Grischott T, Falcato L, Senn O, Puhan MA, Bruggmann P. Chronic obstructive pulmonary disease (COPD) among opioid‐dependent patients in agonist treatment. A diagnostic study. Addiction. 2019; 114(5): 868-76.
    14. Vozoris NT, Wang X, Austin PC, Lee DS, Stephenson AL, O’donnell DE, et al. Adverse cardiac events associated with incident opioid drug use among older adults with COPD. European Journal of Clinical Pharmacology. 2017; 73(10):1287-95.
    15. Vozoris NT, Wang X, Fischer HD, Bell CM, O'Donnell DE, Austin PC, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. European Respiratory Journal. 2016; 48(3):683-93.
    16. Vozoris NT, Wang X, Fischer HD, Gershon AS, Bell CM, Gill SS, et al. Incident opioid drug use among older adults with chronic obstructive pulmonary disease: a population‐based cohort study. British Journal of Clinical Pharmacology. 2016; 81(1): 161-70.
    17. Tantucci C, Modina D. Lung function decline in COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2012; 7: 95.
    18. Walker PP, Thwaite E, Amin S, Curtis JM, Calverley PM. The association between heroin inhalation and early onset emphysema. Chest. 2015; 145 (5):1156-63.
    19. Nightingale R, Mortimer K, Giorgi E, Walker PP, Stolbrink M, Byrne T, et al. Screening heroin smokers attending community drug clinics for change in lung function: a cohort study. Chest. 2020; 157 (3):558-65.
    20. Lange P, Celli B, Agustí A, Boje Jensen G, Divo M, Faner R, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. New England Journal of Medicine. 2015; 373 (2):111-22.
    21. Vanfleteren L, Lamprecht B, Wouters E, Gnatiuc L, Burney P, Studnicka M, et al. The body mass index and chronic obstructive pulmonary disease in the BOLD study. Eur Respiratory Soc. 2013; 42: 4652.
    22. Zhang J, Lin X-f, Bai C-x. Comparison of clinical features between non-smokers with COPD and smokers with COPD: a retrospective observational study. International Journal of Chronic Obstructive Pulmonary Disease. 2014; 9: 57.
    23. Krantz AJ, Hershow RC, Prachand N, Hayden DM, Franklin C, Hryhorczuk DO. Heroin insufflation as a trigger for patients with life-threatening asthma. Chest. 2003; 123 (2): 510-7.
    24. Haim DY, Lippmann ML, Goldberg SK, Walkenstein MD. The pulmonary complications of crack cocaine: a comprehensive review. Chest. 1995;107(1):233-40.
    25. Da Costa J, Tock E, Boey H. Lung disease with chronic obstruction in opium smokers in Singapore: Clinical, electrocardiographic, radiological, functional, and pathological features. Thorax. 1971;26(5):555-71.
    26. Jiang H, Zhang X, Zhang J, Liang J, Wang L. Association between opioid and benzodiazepine use and all-cause mortality in individuals with chronic obstructive pulmonary disease: A pospective cohort study. Int J Chron Obstruct Pulmon Dis. 2024; 30(19):2181-2192.
Medical Journal of Mashhad university of Medical Sciences
Volume 69, Issue 3
May 2026
Pages 250-260

Files

Share

How to cite

Statistics